Search results
Found 132 matches for
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
©
Image credit: Gates Archive/Samantha Reinders
The Kaiya Foundation to fund Leukaemia Research at University of Oxford
1 September 2025
The Kaiya Foundation has awarded one of its first major research grants, which will fund pioneering research into the fundamental cause of a high-risk leukaemia. The grant is being made to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group, based at the University of Oxford, in the hope that their discoveries will transform treatment approaches for sufferers through personalised medicine.
New jab protects babies from serious lung infection, study shows
23 July 2025
Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, research suggests.
Professor Simon Draper elected Fellow of the Academy of Medical Sciences
22 May 2025
Simon Draper, Professor of Vaccinology and Translational Medicine at the Department of Paediatrics and Kavli Institute for Nanoscience Discovery, has been elected as a Fellow to the Academy of Medical Sciences, it has been announced today.
Study shows urgent change needed to reduce deaths from malaria and meningitis in comatose African children
22 April 2025
Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.
Spotlight on Magdalen College Chapel for Rare Disease Day
28 February 2025
The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.
New partnership to advance public health and life science research collaboration in West Africa
13 February 2025
The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics – as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.
New study shows that early support for children living in marginalised communities can improve their developmental outcomes
29 January 2025
Research by experts at the Department of Paediatrics, and published in the European Journal of Paediatrics shows that early interventions of support to the development of children living in disadvantaged settings, can significantly improve their neurodevelopmental outcomes during early childhood.
Oxford and partners lead on two new MRC Centres to create cutting-edge gene therapies
11 December 2024
Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.
Trial results for first vaccine against blood-stage malaria show it is well-tolerated and offers effective protection
10 December 2024
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease – the first inoculation to do so.
Dr. Nicky Whiffin awarded Balfour Lecture 2025
22 November 2024
Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford’s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.
David Cameron resumes role as chair of Advisory Council for Oxford-Harrington Rare Disease Centre (OHC)
16 October 2024
Former UK Prime Minister David Cameron has resumed his role as chair of the OHC Advisory Council, a position he originally undertook in October 2023 prior to his appointment as Foreign Secretary.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease
- Clinical Trials
- Department
- Gastroenterology
- Immunology
- Publication
- Research
- Research Methods
- University
4 August 2024
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
New discovery renews hope for thousands with neurodevelopment disorders
12 July 2024
A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). NDD is a collective term for severe impairments in how the brain functions that impact learning, behaviour, speech, and movement. Most NDDs are thought to be genetic and caused by changes to DNA, however, to date, around 60% of individuals with these conditions do not know the specific DNA change that causes their disorder.
New trial launches for two-in-one vaccine to prevent RSV and hMPV
12 July 2024
Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.
Research shows early life immunity increases HIV cure/remission in male infants
10 June 2024
New research published by scientists at the University of Oxford, the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa, and the Ragon Institute of Mass General, MIT and Harvard, USA, shows that male infants are more likely to achieve HIV cure/remission than females.
GOSH Charity co-funds two data-driven projects to advance research into childhood cancers
29 May 2024
Great Ormond Street Hospital (GOSH) Charity has joined forces with Cancer Research UK (CRUK) to co-fund two projects that will use data science to advance research into childhood cancers.
New research assesses the function of a major genetic cause of neurodevelopmental disorders
22 May 2024
New research, published today, has defined the functional impacts of hundreds of variants in a gene that is a major cause of neurodevelopmental disorders.
Professor Sir Andrew Pollard elected to the Fellowship of the Royal Society
16 May 2024
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.